MSD

Showing 15 posts of 247 posts found.

merckwindow_web

Keytruda success continues, beating Opdivo in lung cancer survival

April 17, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Not content with revealing two strong waves of data on its flagship immunotherapy Keytruda (pembrolizumab) over the past weeks, MSD …

merckentranceweb

Keytruda continues success with new Phase 3 data in adjuvant melanoma

April 16, 2018
Research and Development, Sales and Marketing Cancer, MSD, keytruda, melanoma, pharma, skinc cancer

MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …

msd

Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression

April 10, 2018
Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …

merckincweb

Keytruda combo fails at Phase 3 in metastatic melanoma

April 9, 2018
Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure

Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …

Working Life: Chris Round, Head of EMEA Region, Merck KGaA

March 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chris Round, MSD, Merck, Merck KGaA, Working Life, pharma

Merck KGaA’s Chris Round, Head of EMEA Region, spoke with Pharmafile.com to discuss his time at both the US and …

NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy

March 16, 2018
Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma

UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …

samsung_bioepis

Ontruzant launches to become first Herceptin biosimilar available in the UK

March 8, 2018
Sales and Marketing Cancer, Herceptin, MSD, Ontruzant, Roche, Samsung Bioepis, pharma

Ontruzant, the biosimilar version of Herceptin (trastuzumab ) originally developed by Korean firm Samsung Bioepis, has launched for patients in …

shutterstock_273326141

Eisai and MSD team up to combine Lenvima and Keytruda in cancer

March 8, 2018
Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma

Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

merckincweb

MSD poised to acquire viral immuno-oncology firm Viralytics for $394m

February 21, 2018
Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …

gavel

Long-running, $2.5bn lawsuit swings in Gilead’s favour

February 19, 2018
Sales and Marketing Gilead, MSD, biotech, drugs, harvoni, pharma, pharmaceutical, sovaldi

The fate of pharma company’s profits and losses largely rests on product approvals and the sales team behind them but, …

biogen_austria_238

Biogen shares hit by key Alzheimer’s drug concerns

February 15, 2018
Research and Development Alzheimer's, Biogen, MSD, Merck, biotech, drugs, pharma, pharmaceutical

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …

New biotech facility to bring 350 jobs to Dublin

February 14, 2018
Manufacturing and Production, Research and Development Dublin, Ireland, MSD, pharma

MSD has announced plans to invest in a new biotechnology facility in Dublin which it claims will create 350 jobs …

merckincweb

MSD shuts down Phase 3 trial in prodromal Alzheimer’s

February 14, 2018
Research and Development Alzheimer's, MSD, pharma, verubecestat

Another blow has been dealt to the field of Alzheimer’s research as MSD announces yet another trial failure of a …

european_commission_web

EMA committee recommends seven therapies from Roche, GSK, MSD and more

January 29, 2018
Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …

The Gateway to Local Adoption Series

Latest content